FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens

Primary endpoint

Overall survival

Population

Non Small Cell Lung Cancer; n=742

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The PUFS trial's stated primary conclusion — Pipeline flow-diverter achieves durable occlusion of large and giant internal carotid aneurysms. — replicates in independent cohorts.

neurointerventional

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of PUFS are confirming the original effect size in real-world data.

neurointerventional

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, flow-diverter use will extend to posterior circulation aneurysms with safety non-inferior to anterior-circulation benchmarks.

neurointerventional

Semantically related trials

Nearest trials by noeme-centroid cosine distance. Lower = closer.

NCT01804355

0.1593

· 3 claims

A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke

NCT04402632

0.1626

· 3 claims

A Study of the Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System In the Treatment of Subacute and Chronic Subdural HEmatoma (EMBOLISE)

NCT04816591

0.1709

· 3 claims

Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA

NCT01657461

0.1760

· 3 claims

Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke

NCT01492725

0.1761

· 3 claims

Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection

NCT02586415

0.1777

· 3 claims

Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging